Moderna, Inc. (NASDAQ:MRNA) Given Average Rating of “Hold” by Brokerages

Moderna, Inc. (NASDAQ:MRNA) has been assigned a consensus recommendation of “Hold” from the twenty-four ratings firms that are covering the company, Marketbeat.com reports. Four analysts have rated the stock with a sell recommendation, sixteen have assigned a hold recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $58.70.

Several equities research analysts recently commented on MRNA shares. William Blair restated a “market perform” rating on shares of Moderna in a research report on Thursday, April 17th. Citigroup initiated coverage on Moderna in a report on Thursday, March 13th. They set a “neutral” rating and a $40.00 price target on the stock. Barclays downgraded Moderna from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $111.00 to $45.00 in a research note on Tuesday, February 18th. Berenberg Bank upped their target price on Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a report on Thursday, January 16th. Finally, The Goldman Sachs Group lowered shares of Moderna from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $99.00 to $51.00 in a research report on Wednesday, January 29th.

Moderna Trading Up 3.0 %

NASDAQ MRNA opened at $26.52 on Thursday. Moderna has a 1 year low of $23.15 and a 1 year high of $170.47. The company has a market cap of $10.25 billion, a PE ratio of -2.86 and a beta of 2.23. The stock’s 50-day moving average price is $30.48 and its two-hundred day moving average price is $39.07.

Institutional Investors Weigh In On Moderna

Large investors have recently added to or reduced their stakes in the stock. Wilmington Savings Fund Society FSB raised its position in shares of Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after purchasing an additional 587 shares during the period. Venturi Wealth Management LLC raised its holdings in Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after acquiring an additional 664 shares during the period. Compass Planning Associates Inc acquired a new position in Moderna during the 4th quarter worth $37,000. Crowley Wealth Management Inc. bought a new stake in Moderna during the fourth quarter valued at about $41,000. Finally, Itau Unibanco Holding S.A. grew its position in shares of Moderna by 51.2% in the fourth quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company’s stock valued at $42,000 after purchasing an additional 343 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.